10/24/2024 | Press release | Distributed by Public on 10/24/2024 06:12
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half Life Extended Anti IL 13 Antibody for the Treatment for Atopic Dermatitis and[...]
